Introduction
Marrow fibrosis (MF) is a typical complication of Ph þ chronic myeloid leukemia (CML), shortening the survival time of patients. [1] [2] [3] [4] [5] [6] Whether MF provides prognostic information independent of other significant prognostic factors is discussed controversially. 3, [7] [8] [9] Recently, an independent poor prognostic significance has been detected on basis of a prospective controlled trial. 10 CML responds well to therapy with interferon-a [11] [12] [13] [14] [15] [16] or a tyrosine kinase inhibitor [17] [18] [19] [20] and can be cured by stem cell allografting. However, whereas reversal of MF was reported during tyrosine kinase inhibition or after allografting, 18 -21 the few retrospective results on the effect of interferon-a on MF in CML are controversial ranging from retardation or reversal [22] [23] [24] [25] to progression of fibrosis during therapy with this cytokine. 26, 27 The fact that the data were collected retrospectively, not considering the reasons for taking the bone marrow biopsies (BMBs), may be an explanation because sequential BMBs are usually taken dependent on the individual response to detect either toxic side effects on bone marrow or accelerated phase of the disease, especially when the patient is suspected of having MF (dry tap). Indeed, an antifibrotic effect of interferon-a on fibrosis has recently been reported on the basis of BMBs taken prospectively during the course of disease, 10 thus supporting the results from animal models and in vitro studies showing inhibition of procollagen production and fibroblast growth by this cytokine. [28] [29] [30] However, the possible influences of the interferon dosage and of a combination with cytosine arabinoside have not yet been considered although they may influence the probability of cytogenetic remission. [31] [32] [33] [34] Therefore, BMBs from 200 patients recruited in two prospective therapeutic studies on CML, 16, 32, 35, 36 using different doses of interferon-a with or without cytosine arabinoside, were analyzed with respect to the presence and the evolution of MF. The biopsies had been taken in a prospective manner at defined time intervals according to the design of these studies, regardless of the individual response. To the best of our knowledge, this evaluation is the first allowing an unbiased analysis of the in vivo effect of the interferon-a dose on the evolution of MF during the course of CML.
Patients and methods

Patients and therapy groups
The results presented are based on the BMBs available from a total of 200 patients with Ph þ and/or bcr-abl-positive CML in the chronic phase, who were recruited without age limit in two prospective studies on interferon-a therapy of CML. 16, 32 The first study (Hannover CML study) comprised four successive phase II trials. 32, 36 The initial trial (total of 27 patients) tested the effectiveness of a monotherapy with lowdose interferon-a (3 Â 5 Â 10 6 IU/week subcutaneously). The second trial (total of 10 patients) was performed to test the effectiveness of high-dose interferon-a in patients pretreated with busulfan monotherapy. The third trial (total of 46 patients) tested the efficacy of high-dose monotherapy with interferon-a in nonpretreated patients with newly diagnosed CML in the chronic phase. These patients received a short induction therapy with busulfan for 4 weeks (0.05 mg/kg body weight). In the second and the third trial, the interferon-a monotherapy was started with 3 Â 10 Â 10 6 IU/week (subcutaneously), and the dosage was increased up to the maximum tolerated by the patient (no severe side effects; leukocytes 42 Â 10 9 /l blood). The fourth trial (total of 63 patients) tested the effectiveness of combined interferon-a plus cytosine arabinoside therapy starting interferon-a at 3 Â 10 6 IU/m 2 /per day subcutaneously, and adding cytosine arabinoside after 1 week at 5 Â 20 mg/m 2 /per week. Subsequently, the interferon dosage was increased to 6 Â 10 6 IU/m 2 per day. When the white blood cell count fell below 2 Â 10 9 /l, the cytosine arabinoside therapy was discontinued. 36 A total of 90 patients of the Hannover CML study with sufficient BMBs before and/or during therapy were evaluated for the extent of fibrosis in bone marrow: 19 of the first, seven of the second, 34 of the third, and 30 of the fourth trial. In all, 18/90 patients had been pretreated with busulfan for 3.072.4 years in mean (7s.d.). In the following, the patients of the second and the third trials are combined in the group 'high-dose interferona' ( Table 1) .
The interferon group of a second prospective phase III study on Ph þ CML (total of 133 patients; German CML Study I) was used to allow a validation of results. They had not been pretreated and were randomized to receive high-dose interferon-a (5 Â 10 6 IU/m 2 per day or maximum dose tolerated). 16 Their results with respect to the risk of MF have recently been compared to those during chemotherapy on a random basis. 10 The potential significance of the interferon dosage that was individually adapted during the course of disease dependent on side effects and tolerability of therapy has not been considered as yet. In all, 110/133 patients with sufficient BMBs could be evaluated for the extent of fibrosis in bone marrow ( Table 1 ).
The patients evaluated for bone MF did not differ from the remaining patients of both studies who lacked sufficient bone marrow biopsies taking into consideration initial data (age, sex, peripheral blood findings, spleen size), and course of disease (duration of chronic phase, survival times; not illustrated).
Evaluation and study design
A hematologic remission was defined as described earlier. 16 During the period of observation, 36.5% of patients achieved a partial and 38.5% a complete response. Data on the percentage of Ph þ cells in bone marrow with more than 20 metaphases evaluated on a day when a BMB had been taken were available from 185 patients; 16.1% of them had a minimal or minor cytogenetic response (o95-35% Ph þ metaphases), 18.8% a partial or complete remission (o35% Ph þ metaphases) during the therapy periods analyzed. BMBs from 35 patients could be correlated with additional aberrations besides the t(9;22) in at least two metaphases on or before the days when the BMBs had been taken.
Resistance to therapy was diagnosed in the case of no hematologic remission within 4 months after start of therapy or in the case of progressive disease in spite of increasing doses of interferon-a or when a blast crisis occurred. A blast crisis was diagnosed when the blast count exceeded 30% of peripheral white blood cells or of nucleated cells in the bone marrow. A total of 100 patients developed treatment resistance during the course of disease. A total of 131 patients died during the followup evaluation.
When analyzing the survival times during interferon-a therapy, the follow-up evaluations of the 43 patients who received a bone marrow transplant were censored at the time of transplantation. The time interval from diagnosis to allografting 
Morphometric examinations of bone marrow
MF was measured exactly to achieve precise and reproducible results. A new approach was applied quantifying the volume ratio V MF of marrow affected by fibrosis, since this parameter appears to be crucial for the prognostic significance of MF in CML. 10, 37 Briefly, each biopsy section was subdivided into 250 virtual squares of equal size, each square was measured whether or not it covered an area exceeding a critical fiber density unusual for healthy, but typical for fibrotic marrow, and the volume ratio V MF of marrow affected by fibrosis was estimated by the proportion of squares exceeding the critical fiber density. 37 Marrow areas free of bone and artefacts were investigated, comprising 11.174.8 mm 2 on average. The time consumption of measurements was B20 min/slide.
Statistical analyses
Time-dependent mean values V V MF on any day d þ 1 were sequentially calculated on the basis of the individual measurement by adding the mean increment to the mean value on day d based on the values of all patients with valid values up to at least day d þ 1. To test the effect of interferon-a on the development of MF, V MF was entered as a dependent variable in the stepwise multiple regression analysis allowing for multiple, time-dependent and correlated measurements within each patient by applying the mixed-effect regression model. 38 Since all patients of the German CML Study received high-dose interferon-a, a time-dependent approach was applied when analyzing the data of these patients by considering the dose adaptation during the course of disease, relating V MF to two periods of time, the mean periods since start of therapy when the interferon dosage exceeded the initial dose (5 Â 10 6 IU/m 2 daily) vs the mean intervals when lower doses were applied.
The Cox proportional hazard regression model was used to test the prognostic significance. The change in the hazard ratio for a unit increase (continuous variable) or occurrence of a category (categorical variable) was used to estimate the relative risk of the event (death, treatment resistance). Variables not changing during therapy were handled as time-constant covariates, while all the others were included as time-dependent covariates, programming polygons on the basis of the findings on the days when the BMBs were taken. The end of the chronic phase, that is, the beginning of the accelerated phase, was defined by the day on which a resistance was detected. Since we could not detect any superiority of the Sokal index to the New CML score 9 (not illustrated), the Sokal index was not considered when testing the prognostic significance of variables.
The influence of MF before transplantation on survival after allografting was analyzed by considering the extent of fibrosis in the last biopsy before transplantation, the time interval t until the day when this biopsy was taken and the interaction between t and the extent of fibrosis in this biopsy since (1) the majority of patients who received a bone marrow transplant were biopsied only once before allografting and (2) the extent of MF correlated with the time interval since diagnosis of disease.
The results from each study were compared with the results from the other study, testing each variable for the difference in the prognostic effect between the patient samples in the two studies.
Results
Influence of therapy
In both study groups, the extent of MF during the course of CML depended on three variables: the extent of fibrosis at the beginning of therapy, the time interval since start of treatment, and the interferon-a dose applied (Po0.000005; Table 2 ; Figure 1 ). Whereas the marrow volume with fibrosis significantly increased during treatment with low-dose interferon-a, the evolution of MF was prevented or reversed by the therapy regimes using interferon-a in high dose (multiple regression; Po0.000005; Table 2 ; Figure 1 ). The combination of interferona with cytosine arabinoside was slightly inferior to the high-dose interferon-a monotherapy during the first year of treatment. However, 2 years later, MF was completely reversed in this patient group (Table 2; Figure 1a ). The development of MF during interferon-a treatment did not differ between untreated and pretreated patients (Hannover CML Study; not illustrated), and the pretreatment did not influence the results during the course of disease (Table 2 ). In the bone marrow of the patients treated with low-dose interferon-a, MF disappeared within 6 months after change to high-dose interferon-a (n ¼ 5; Hannover CML Study; not illustrated).
Relation to cytogenetics and therapy resistance
The development of MF during the course of CML could not be predicted by cytogenetic evaluation of bone marrow, neither by the detection of additional aberrations besides t(9;22), nor by the cytogenetic response (P40.05, multiple regression, not illustrated). MF did not regress during short periods of cytogenetic remission (less than 6 months with o35% Ph þ metaphases). Reversal of MF occurred independently of a cytogenetic remission, and a cytogenetic response either did not occur at all or disappeared when MF evolved or progressed during therapy. The poor correlation to the cytogenetic results was a consistent finding in both studies.
A progressive MF turned out to be the only predictive indicator of evolving treatment resistance in both studies, and the risk of accelerated phase increased by a factor of 5 when fibrosis evolved or progressed (P ¼ 0.0015; multivariate analysis; Table 3, Figure 2b ). The predictive impact of MF was independent of the interferon dosage and of all the other parameters taken into consideration ( Table 3 ). The effect of the hematologic remission differed between the two studies (Po0.00005; Table 3 ).
Prognostic significance of MF
MF turned out to be an important poor prognostic factor independent of all the other parameters evaluated with regard to the survival periods during interferon-a therapy as well as after allografting (multivariate analyses; Tables 4 and 5; Figure 2a) . The New CML Score as well as the hematologic and cytogenetic remissions were further independent factors for survival during interferon-a therapy (Table 4) , whereas the higher age of patients and lower interferon dosage during the period before allografting were further unfavorable independent parameters for the survival after transplantation (Table 5) . Although the prognostic effects of accelerated phase (treatment resistance, blast phase) on the basis of peripheral blood findings, spleen size, and marrow blast count, the occurrence of additional chromosome aberrations beside t(9;22) and the time interval until allografting were significant in univariate analyses (Po0.05); these variables did not provide independent prognostic information besides the extent of fibrosis in the bone marrow (multivariate analyses; Tables 4 and 5 ). Except for the hematologic remission, the prognostic relevance of all parameters analyzed did not differ between the German and the Hannover CML studies (Tables 4  and 5 ).
Discussion
On the basis of both patient groups evaluated, the interferon dose turned out to significantly influence the evolution of MF during the course of CML, a novel finding not previously reported: fibrosis increased markedly during the application of low-dose interferon-a, but did not progress or was even reversed during high doses of interferon-a. Thus, the poor efficacy of lowdose interferon-a well explains the few reports on progressive MF during interferon-a therapy of CML since these patients had 
Figure 1
Extent of marrow fibrosis V MF and interferon (IFN) dosage applied (mean V V MF and regression curves): In both therapy studies, an inverse relation between IFN dosage and development of V MF was detected. MF reversed when high-dose IFN was combined with lowdose cytosine arabinoside (araC). The standard errors were printed on the days when the BMBs had been taken.
Interferon-a dose and MF in CML G Buesche et al been treated with low doses. 26, 27 The inverse correlation to the interferon dose was detected in both studies evaluated. MF even completely disappeared when combining high-dose interferon-a with low-dose cytosine arabinoside. Therefore, an antifibrotic in vivo effect of interferon-a could be ascertained supporting results from animal models and earlier in vitro evaluations [28] [29] [30] and confirming a recent comparison of interferon-a with chemotherapy on a random basis. 10 The favorable response of MF to the combination of high-dose interferon-a with low-dose cytosine arabinoside, furthermore, is in agreement with superior cytogenetic response rates and prolonged survival of patients observed in two randomized studies comparing this combination with interferon-a monotherapy. 31, 33 Thus, MF can be reversed not only by applying imatinib mesylate or allografting, [18] [19] [20] [21] but also by combining high-dose interferon-a with lowdose cytosine arabinoside. However, in contrast to imatinib mesylate that may reverse MF within few weeks to months, [18] [19] [20] there is some delay in the antifibrotic effect of interferon-a resulting in reversal of MF several months to few years after start of treatment.
In both studies, evolving MF was well explained by progressive CML, not only due to an insufficient dosage but also in the case of resistance against interferon-a. Evolving or progressive MF turned out to be an early and reliable predictor of oncoming treatment resistance, an observation consistently detected in both studies supporting recent results from a comparison of interferon-a and chemotherapy on a random basis. 10 The relevance of this observation is underlined by the results from the multivariate analyses: no other variable was able to predict a resistance of CML to therapy except for the hematologic response but, in contrast to MF, the effect of the hematologic remission differed between the therapy studies.
The early prediction of therapy failure may explain why MF turned out to be more important to the survival of patients than the definition of accelerated phase on the basis of peripheral blood findings, spleen size, and marrow blast count, regardless of considering the survival during interferon-a therapy or after allografting. The prognostic significance of MF detected in both therapy studies, therefore, confirms the prognostic relevance of the loss of marrow volume due to fibrosis in CML, as indicated by a systematic comparison of different approaches to quantify MF. 37 Differences to other reports having applied a less-precise and less-sensitive approach and not focusing on the loss of marrow volume as an important consequence of fibrosis 8 should be discussed against this background. The long-term observations of both therapy studies analyzed indicate that the disregard of MF in the majority of therapy trials on CML is not justified from the prognostic point of view.
The prognostic relevance of MF did not depend on the way in which the cytogenetic remission was taken into consideration Table 3 Prediction of therapy resistance: multivariate analysis with comparison of the effects of variables in both therapy studies Relative risk ¼ estimated change in the hazard rate; NS ¼ not significant. The follow-up evaluations of patients receiving a bone marrow transplant were censored on the day of transplantation. The risk of therapy resistance increased by a factor of 5 when MF occurred or progressed, a a finding valid in both the therapy studies, b whereas the effect of the hematologic response differed between the two studies (Po0.00005; independent prognostic relevance in the German CML Study I, not in the Hannover CML Study).
Figure 2
Prognostic significance of the development of MF one and two years after start of therapy: In both therapy studies, the further course of disease depended on the extent of fibrosis V MF 1 (a) and 2 (b) years after onset of therapy (a: survival; b: accelerated phase/detection of therapy resistance; patients of both studies with adequate biopsies at these points in time; since less than five patients showed a biopsy with extensive fibrosis V MF 40.50 two years after onset of therapy, a separate curve was not printed at this point in time).
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(maximum response vs time-dependent analysis), a finding valid in both studies. From the statistical point of view, the independence of the prognostic significance of both marrow variables should not be a surprise since (1) MF indicates progression of CML, the cytogenetic response remission of disease and (2) both variables of bone marrow did not closely correlate, a consistent observation in both the studies evaluated. The low correlation between the cytogenetic response and the extent and development of MF was also observed by other authors during interferon-a as well as during tyrosine kinase inhibition. 18, 22 However, whereas the antifibrotic effect of imatinib mesylate can be explained by a selective inhibition of an important mediator of fibrogenesis in CML, the platelet-derived growth factor (PDGF) receptor protein kinase, 39 the effect of interferona on MF is not well understood as yet. Obviously, the antifibrotic effect of interferon-a cannot only be explained by a quantitative reduction of the Ph þ cell clone in bone marrow. The inhibition of CML from progressing may be an explanation, as indicated by the correlation of MF with oncoming therapy resistance. Inhibitory effects on fibroblasts as well as on cells inducing fibroblasts to produce fibers -such as megakaryocytes -may be other reasons, as indicated by in vitro examinations. 29, 30, 40 The prognostic significance of MF was furthermore independent of two other important prognostic factors, the risk score before onset of therapy and the hematologic remission during treatment. Interestingly, in both patient groups, the New CML Score provided independent prognostic information only with respect to overall survival times of patients whereas the hematologic respose was more relevant to the survival times in chronic phase. However, considering that (1) the New CML except for the hematologic response (Po0.00005; independent prognostic relevance in the Hannover CML study, but not in the German CML Study I).
c ¼ survival times in chronic phase, that is disregarding the periods after detection of accelerated phase. Relative risk ¼ estimated change in the hazard rate; NS ¼ not significant. Patients were excluded from multivariate analysis if data of any variable included in the model were missing. The risk of death after allografting increased by a factor of 20 when MF had evolved or progressed during the therapy period before transplantation. The prognostic effect of variables did not differ a between the two therapy studies or b between the high-dose groups of both studies.
c V MF in the last biopsy before transplantation Â time interval since start of therapy.
Score had been developed with respect to the overall survival times of patients, not with respect to the survival times in chronic phase, 9 whereas (2) the hematologic remission is an important predictor of the end of chronic phase, these observations should not be a surprise.
The independence of the prognostic significance of MF from risk score before onset of treatment, cytogenetic and hematologic remission and from accelerated phase confirms recent results from a comparison of high-dose interferon-a with chemotherapy on a random basis. 10 It was not previously validated since prospective long-term evaluations of MF during the course of CML were lacking.
In summary:
(1) MF is a typical complication of Ph þ CML affecting the majority of patients during the course of disease when therapy is not effective. ( 2) The effectiveness of interferon-a on MF depends on the dose applied, a significant inverse correlation not considered before: high-dose interferon-a is antifibrotic, preventing MF from progression, or reversing it particularly if combining with cytosine arabinoside, whereas low-dose interferon-a is ineffective. (3) Developing or increasing MF is an early indicator of progressive CML and therapy failure with significant shortening of survival time regardless of whether the patients are treated with interferon-a or with allografting. The prognostic significance of this complication appears to be independent of all the other standard prognostic factors of CML.
